Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.
Posted 12 February 2018 | By Michael Mezher
The US Food and Drug Administration (FDA) on Monday finalized guidance providing recommendations to drugmakers for developing new drugs and biologics to treat bacillus Calmette-Guérin (BCG)-unresponsive nonmuscle invasive bladder cancer (NMIBC), the most prevalent form of bladder cancer in the US.
Intravesical immunotherapy with live attenuated BCG remains the standard of care for patients with bladder cancer. However, to date FDA has approved just one other therapy for NMIBC, Valstar (valrubicin), which the Bladder Cancer Advocacy Network (BCAN) says has a "very limited indication and has limited efficacy."
The supply of BCG has also been constrained in recent years as Sanofi Aventis, one of two companies that recently manufactured BCG stopped production of the therapy in 2016, leaving NMIBC patients with limited treatment options.
In terms of changes between the draft and final guidance, FDA said: "In addition to editorial changes made primarily for clarification, noteworthy substantive changes are as follows: clarification of the definition of BCG-unresponsive disease and detailed information concerning the definition of complete response."
The guidance finalizes a draft version released in November 2016 and follows discussions held at the FDA/American Urological Association Bladder Cancer Workshop in May 2013.
While FDA says the recommendations made in the guidance can apply to drugs intended to treat BCG-unresponsive NMIBC and other forms of NMIBC, its recommendations may not apply in all cases and FDA says that sponsors should discuss their specific development plans with the agency.
For drugmakers looking to develop products to treat BCG-unresponsive NMIBC, FDA says the clinical endpoint chosen should depend on whether patients in the study have active disease at the time of enrollment.
"For patients without active disease (disease was reseected at or before trial entry), FDA recommends a randomized, controlled trial design using a time-to-event endpoint such as recurrence-free survival. In contract, patients with carcinoma in situ (CIS) at trial entry can be studied in either a randomized, controlled trial or a single-arm trial," FDA writes.
FDA notes that in BCG-unresponsive NMIBC, a single-arm study measuring complete response rate and duration of response can be sufficient to demonstrate effectiveness.
For sponsors looking to develop systemic therapies for BCG-unresponsive NMIBC, FDA says that early stage trials should be limited to patients with few other treatment options due to heightened safety concerns with systemic drugs.
FDA, Federal Register Notice